SMT202000064T1 - Anticorpi monoclonali al fattore di crescita e differenziazione 15 (gdf-15), e loro usi per trattare la cachessia da cancro e il cancro - Google Patents
Anticorpi monoclonali al fattore di crescita e differenziazione 15 (gdf-15), e loro usi per trattare la cachessia da cancro e il cancroInfo
- Publication number
- SMT202000064T1 SMT202000064T1 SM20200064T SMT202000064T SMT202000064T1 SM T202000064 T1 SMT202000064 T1 SM T202000064T1 SM 20200064 T SM20200064 T SM 20200064T SM T202000064 T SMT202000064 T SM T202000064T SM T202000064 T1 SMT202000064 T1 SM T202000064T1
- Authority
- SM
- San Marino
- Prior art keywords
- cancer
- gdf
- growth
- monoclonal antibodies
- differentiation factor
- Prior art date
Links
- 206010006895 Cachexia Diseases 0.000 title 1
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000004069 differentiation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1405477.9A GB2524553C (en) | 2014-03-26 | 2014-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia |
| GB1405475.3A GB2524552B (en) | 2014-03-26 | 2014-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
| PCT/EP2015/056654 WO2015144855A1 (en) | 2014-03-26 | 2015-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
| EP15712629.3A EP3122775B1 (en) | 2014-03-26 | 2015-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202000064T1 true SMT202000064T1 (it) | 2020-03-13 |
Family
ID=52745885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20200064T SMT202000064T1 (it) | 2014-03-26 | 2015-03-26 | Anticorpi monoclonali al fattore di crescita e differenziazione 15 (gdf-15), e loro usi per trattare la cachessia da cancro e il cancro |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20170204174A1 (enExample) |
| EP (3) | EP3122775B1 (enExample) |
| JP (3) | JP6865585B2 (enExample) |
| KR (1) | KR102520978B1 (enExample) |
| CN (1) | CN106536553B (enExample) |
| AU (2) | AU2015238264B2 (enExample) |
| BR (1) | BR122023027559A2 (enExample) |
| CA (1) | CA2943694A1 (enExample) |
| CY (1) | CY1122456T1 (enExample) |
| DK (2) | DK3122775T3 (enExample) |
| ES (2) | ES2763859T3 (enExample) |
| FI (1) | FI3653644T3 (enExample) |
| HR (2) | HRP20231514T1 (enExample) |
| HU (2) | HUE047398T2 (enExample) |
| IL (2) | IL248038B (enExample) |
| LT (2) | LT3122775T (enExample) |
| NZ (1) | NZ724649A (enExample) |
| PL (2) | PL3122775T3 (enExample) |
| PT (2) | PT3653644T (enExample) |
| RS (1) | RS59700B1 (enExample) |
| SI (1) | SI3122775T1 (enExample) |
| SM (1) | SMT202000064T1 (enExample) |
| WO (1) | WO2015144855A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3122775T3 (da) | 2014-03-26 | 2020-02-03 | Univ Wuerzburg J Maximilians | Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer |
| EP3197493B1 (en) | 2014-09-25 | 2021-03-10 | Aveo Pharmaceuticals Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
| AU2016333538B2 (en) * | 2015-10-02 | 2022-03-31 | Julius-Maximilians-Universität Würzburg | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| GB201517528D0 (en) * | 2015-10-02 | 2015-11-18 | Julius Maximillians Universitãt Würzburg | GDF-15 as a diagnosis marker for melanoma |
| BR112018006218A2 (pt) | 2015-10-02 | 2018-10-09 | Univ Wuerzburg J Maximilians | iinibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15 |
| JP7138567B2 (ja) * | 2016-04-27 | 2022-09-16 | ノバルティス アーゲー | 成長分化因子１５に対する抗体およびそれらの使用 |
| MX389765B (es) * | 2016-07-06 | 2025-03-20 | Nat Res Council Canada | Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos. |
| JP2020503842A (ja) * | 2016-10-12 | 2020-02-06 | ヤンセン バイオテツク，インコーポレーテツド | Ｇｄｆ１５様生物活性の調節因子をスクリーニングするための方法 |
| CA3045700A1 (en) * | 2016-12-06 | 2018-06-14 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
| KR102715542B1 (ko) * | 2018-08-20 | 2024-10-08 | 화이자 인코포레이티드 | 항-gdf15 항체, 조성물 및 사용 방법 |
| AU2021376864A1 (en) * | 2020-11-10 | 2023-06-29 | Catalym Gmbh | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer |
| BR112023020152A2 (pt) | 2021-03-31 | 2023-11-14 | Cambridge Entpr Ltd | Inibidores terapêuticos de sinalização gdf15 |
| US20250019427A1 (en) | 2021-08-10 | 2025-01-16 | Byomass Inc. | Anti-gdf15 antibodies, compositions and uses thereof |
| WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
| WO2023217068A1 (zh) | 2022-05-09 | 2023-11-16 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别gdf15的抗体及其应用 |
| CN116462757A (zh) * | 2023-03-24 | 2023-07-21 | 科兴生物制药股份有限公司 | Gdf15的单域抗体及其应用 |
| CN118878677A (zh) * | 2024-09-29 | 2024-11-01 | 江苏凯基生物技术股份有限公司 | 一种IgM亚型单克隆抗体及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| DE60032355T2 (de) | 1999-05-17 | 2007-04-26 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh | NEUROPROTEKTIVE EIGENSCHAFTEN VON GDF-15, EINEM VERTRETER DER TGF-ß-SUPERFAMILIE |
| AU2001288770A1 (en) | 2000-09-08 | 2002-03-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| EP3476861A1 (en) * | 2004-01-07 | 2019-05-01 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
| ES2555956T3 (es) * | 2004-04-13 | 2016-01-11 | St Vincent's Hospital Sydney Limited | Método para modular el apetito |
| WO2009021293A1 (en) * | 2007-08-16 | 2009-02-19 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| JP2011502106A (ja) * | 2007-10-09 | 2011-01-20 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法 |
| WO2010034443A1 (en) | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| US9212221B2 (en) * | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| TR201802772T4 (tr) * | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| EP2565262A1 (en) | 2011-08-31 | 2013-03-06 | VTU Holding GmbH | Protein expression |
| MX2014009129A (es) | 2012-01-26 | 2014-11-21 | Amgen Inc | Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15). |
| EP3590537A1 (en) * | 2012-09-26 | 2020-01-08 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| WO2014100689A1 (en) * | 2012-12-21 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| DK3122775T3 (da) | 2014-03-26 | 2020-02-03 | Univ Wuerzburg J Maximilians | Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer |
-
2015
- 2015-03-26 DK DK15712629.3T patent/DK3122775T3/da active
- 2015-03-26 NZ NZ724649A patent/NZ724649A/en unknown
- 2015-03-26 HU HUE15712629A patent/HUE047398T2/hu unknown
- 2015-03-26 SM SM20200064T patent/SMT202000064T1/it unknown
- 2015-03-26 CN CN201580027932.8A patent/CN106536553B/zh active Active
- 2015-03-26 AU AU2015238264A patent/AU2015238264B2/en active Active
- 2015-03-26 PL PL15712629T patent/PL3122775T3/pl unknown
- 2015-03-26 PT PT192053213T patent/PT3653644T/pt unknown
- 2015-03-26 US US15/128,604 patent/US20170204174A1/en not_active Abandoned
- 2015-03-26 FI FIEP19205321.3T patent/FI3653644T3/fi active
- 2015-03-26 HU HUE19205321A patent/HUE064573T2/hu unknown
- 2015-03-26 JP JP2016559286A patent/JP6865585B2/ja active Active
- 2015-03-26 EP EP15712629.3A patent/EP3122775B1/en active Active
- 2015-03-26 HR HRP20231514TT patent/HRP20231514T1/hr unknown
- 2015-03-26 LT LTEP15712629.3T patent/LT3122775T/lt unknown
- 2015-03-26 EP EP23203704.4A patent/EP4316596A3/en active Pending
- 2015-03-26 DK DK19205321.3T patent/DK3653644T5/da active
- 2015-03-26 CA CA2943694A patent/CA2943694A1/en active Pending
- 2015-03-26 HR HRP20200034TT patent/HRP20200034T1/hr unknown
- 2015-03-26 BR BR122023027559-4A patent/BR122023027559A2/pt not_active Application Discontinuation
- 2015-03-26 EP EP19205321.3A patent/EP3653644B1/en active Active
- 2015-03-26 RS RS20191652A patent/RS59700B1/sr unknown
- 2015-03-26 ES ES15712629T patent/ES2763859T3/es active Active
- 2015-03-26 PL PL19205321.3T patent/PL3653644T3/pl unknown
- 2015-03-26 SI SI201531059T patent/SI3122775T1/sl unknown
- 2015-03-26 WO PCT/EP2015/056654 patent/WO2015144855A1/en not_active Ceased
- 2015-03-26 LT LTEP19205321.3T patent/LT3653644T/lt unknown
- 2015-03-26 ES ES19205321T patent/ES2965626T3/es active Active
- 2015-03-26 KR KR1020167029710A patent/KR102520978B1/ko active Active
- 2015-03-26 PT PT157126293T patent/PT3122775T/pt unknown
-
2016
- 2016-09-26 IL IL248038A patent/IL248038B/en active IP Right Grant
-
2018
- 2018-03-05 US US15/912,358 patent/US10604565B2/en active Active
-
2020
- 2020-01-08 CY CY20201100008T patent/CY1122456T1/el unknown
- 2020-02-19 US US16/794,401 patent/US11634482B2/en active Active
- 2020-02-19 US US16/794,406 patent/US11760795B2/en active Active
- 2020-07-30 IL IL276405A patent/IL276405B/en unknown
- 2020-10-28 AU AU2020260440A patent/AU2020260440B2/en active Active
-
2021
- 2021-04-06 JP JP2021064572A patent/JP7607498B2/ja active Active
-
2023
- 2023-04-06 JP JP2023062338A patent/JP2023098966A/ja not_active Withdrawn
- 2023-08-02 US US18/364,173 patent/US20230382987A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276405B (en) | Monoclonal antibodies to factor 15 (gdf-15) for growth and differentiation, and their use for the treatment of cancerous tumors and cancer | |
| IL287051A (en) | Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer | |
| IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
| IL267804A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| IL270596A (en) | Antibodies containing heavy constant regions are adapted for use in cancer therapy | |
| IL253462B2 (en) | Cancer treatment with monoclonal antibodies against a latency-related peptide | |
| PT3063173T (pt) | Anticorpos anti-cd38 específicos para o tratamento de cancros humanos | |
| IL260474B (en) | Antibodies specific to cadherin-17 and cytotoxic cells for cancer treatment | |
| IL277861A (en) | Antibodies specific to AXL for cancer treatment | |
| LT4339615T (lt) | Antikūnai prieš pd-1, skirti naudoti vėžio gydymui | |
| SG11201704792UA (en) | Anti-csf1r antibodies for treating pvns | |
| TWI560201B (en) | Bi-specific antibodies for treating cancer | |
| SG11201507354QA (en) | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment | |
| SG11201702103XA (en) | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment | |
| IL250507B (en) | Anti-ck8 antibodies for use in cancer treatment | |
| GB2524553B (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia | |
| GB2524552B (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer | |
| ZA201707117B (en) | Antibody compositions for tumor treatment |